AQR Capital Management LLC boosted its holdings in shares of MacroGenics Inc (NASDAQ:MGNX) by 31.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,870 shares of the biopharmaceutical company’s stock after buying an additional 3,751 shares during the quarter. AQR Capital Management LLC’s holdings in MacroGenics were worth $269,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in MGNX. Marshall Wace LLP acquired a new stake in MacroGenics during the 1st quarter worth approximately $80,000. Marshall Wace North America L.P. acquired a new stake in MacroGenics during the 1st quarter worth approximately $59,000. Sphera Funds Management LTD. acquired a new stake in MacroGenics during the 1st quarter worth approximately $4,225,000. Aperio Group LLC lifted its holdings in MacroGenics by 80.4% during the 2nd quarter. Aperio Group LLC now owns 27,955 shares of the biopharmaceutical company’s stock worth $474,000 after buying an additional 12,461 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in MacroGenics by 12.8% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 750,988 shares of the biopharmaceutical company’s stock worth $12,688,000 after buying an additional 85,500 shares in the last quarter. Institutional investors own 95.89% of the company’s stock.
A number of research firms have issued reports on MGNX. Stifel Nicolaus reduced their target price on shares of MacroGenics from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. ValuEngine lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Monday, July 8th. Zacks Investment Research lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Thursday, October 3rd. Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of MacroGenics in a report on Thursday, July 18th. Finally, BidaskClub lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Friday, July 19th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company’s stock. MacroGenics presently has an average rating of “Buy” and an average target price of $30.98.
Shares of MGNX opened at $11.38 on Friday. MacroGenics Inc has a twelve month low of $9.87 and a twelve month high of $32.32. The firm’s fifty day simple moving average is $13.16 and its 200-day simple moving average is $15.68. The firm has a market capitalization of $556.40 million, a price-to-earnings ratio of -2.72 and a beta of 2.34. The company has a current ratio of 5.81, a quick ratio of 5.81 and a debt-to-equity ratio of 0.08.
MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.96) by $0.31. MacroGenics had a negative net margin of 273.47% and a negative return on equity of 54.52%. The business had revenue of $10.59 million for the quarter, compared to analyst estimates of $17.58 million. On average, analysts predict that MacroGenics Inc will post -3.24 earnings per share for the current fiscal year.
MacroGenics Company Profile
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Featured Story: Why do companies engage in swaps?
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.